These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11586113)

  • 41. A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice.
    Sankar R; Ramsay E; McKay A; Hulihan J; Wiegand F;
    Epilepsy Behav; 2009 Aug; 15(4):506-12. PubMed ID: 19643672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group.
    Faught E; Wilder BJ; Ramsay RE; Reife RA; Kramer LD; Pledger GW; Karim RM
    Neurology; 1996 Jun; 46(6):1684-90. PubMed ID: 8649570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topiramate monotherapy for childhood absence seizures: an open label pilot study.
    Cross JH
    Seizure; 2002 Sep; 11(6):406-10. PubMed ID: 12160672
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of topiramate on intractable seizures in Taiwanese children.
    Li ST; Shen EY; Chiu NC; Ho CS
    Acta Neurol Taiwan; 2004 Jun; 13(2):59-63. PubMed ID: 15478676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group.
    Privitera M; Fincham R; Penry J; Reife R; Kramer L; Pledger G; Karim R
    Neurology; 1996 Jun; 46(6):1678-83. PubMed ID: 8649569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topiramate: a review of preclinical, pharmacokinetic, and clinical data.
    Rosenfeld WE
    Clin Ther; 1997; 19(6):1294-308. PubMed ID: 9444441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Add-on topiramate in the treatment of refractory partial-onset epilepsy: clinical experience of outpatient epilepsy clinics from 11 general hospitals.
    Giannakodimos ST; Georgiadis G; Tsounis ST; Triantafillou N; Kimiskidis V; Giatas K; Karlovasitou A; Mitsikostas DD; Thodi E; Polychronopoulos P; Ramopoulos N; Michailidis K; Michalis N; Garganis K; Gatzonis ST; Balogiannis ST; Kazis AR; Milonas J; Van Oene JC
    Seizure; 2005 Sep; 14(6):396-402. PubMed ID: 16019237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical experience with open-label topiramate use in infants younger than 2 years of age.
    Watemberg N; Goldberg-Stern H; Ben-Zeev B; Berger I; Straussberg R; Kivity S; Kramer U; Brand N; Lerman-Sagie T
    J Child Neurol; 2003 Apr; 18(4):258-62. PubMed ID: 12760428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience.
    Mohamed K; Appleton R; Rosenbloom L
    Seizure; 2000 Mar; 9(2):137-41. PubMed ID: 10845739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seizure and cognitive outcomes in children and adolescents with epilepsy treated with topiramate.
    Brandl U; Kurlemann G; Neubauer B; Rettig K; Schäuble B; Schreiner A
    Neuropediatrics; 2010 Jun; 41(3):113-20. PubMed ID: 20859829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of adjunctive topiramate on cognitive function in patients with epilepsy.
    Lee S; Sziklas V; Andermann F; Farnham S; Risse G; Gustafson M; Gates J; Penovich P; Al-Asmi A; Dubeau F; Jones-Gotman M
    Epilepsia; 2003 Mar; 44(3):339-47. PubMed ID: 12614389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topiramate and psychiatric adverse events in patients with epilepsy.
    Mula M; Trimble MR; Lhatoo SD; Sander JW
    Epilepsia; 2003 May; 44(5):659-63. PubMed ID: 12752464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Riva R; Albani F; Avoni P; Baruzzi A
    Ther Drug Monit; 2002 Jun; 24(3):332-7. PubMed ID: 12021622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Topiramate for intractable childhood epilepsy.
    Moreland EC; Griesemer DA; Holden KR
    Seizure; 1999 Feb; 8(1):38-40. PubMed ID: 10091847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Topiramate in migraine prevention: a double-blind, placebo-controlled study.
    Storey JR; Calder CS; Hart DE; Potter DL
    Headache; 2001; 41(10):968-75. PubMed ID: 11903524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning.
    Werz MA; Schoenberg MR; Meador KJ; Loring DW; Ray PG; Kaul-Gupta R; Ogrocki P
    Epilepsy Behav; 2006 Feb; 8(1):181-91. PubMed ID: 16377253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting.
    Guerrini R; Carpay J; Groselj J; van Oene J; Schreiner A; Lahaye M; Schwalen S;
    Seizure; 2005 Sep; 14(6):371-80. PubMed ID: 15961326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Topiramate: new indication. Single-agent therapy in refractory epilepsy: for a few patients only.
    Prescrire Int; 2004 Oct; 13(73):165-7. PubMed ID: 15499695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Psychosis following treatment with topiramate].
    Verhoeven WM; Boermans JA; van der Heijden FM; Tuinier S
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2093-5. PubMed ID: 12448965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of low dose of topiramate following rapid titration in multiply handicapped children and difficult-to-treat epilepsy.
    Kluger G; Schäuble B; Rettig K; Schreiner A; Holthausen H
    Neuropediatrics; 2009 Apr; 40(2):61-5. PubMed ID: 19809933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.